Their research will be recognized with the Knee Society Award for the best work on a surgical technique at the American Academy of Orthopedic Surgeons annual meeting, February 7-11 in San Francisco. Their initial study findings will be presented on Friday, February 10th at 5:42 PM Pacific Time.
The randomized, double-blind trial administered either bupivacaine, a common analgesic, or normal saline intraoperatively through a catheter in the joint to 150 primary, unilateral knee replacement patients.
The catheters released fluid continually over two postoperative days. Patients were asked to complete questionnaires at 5 PM on the day of surgery and 8 AM and 5 PM each day until discharge, as well as at a four-week follow-up visit.
Patients who received bupivacaine reported receiving the least pain and the lowest narcotic consumption. There was also no significant different in postoperative complications.
The study concludes that knee replacement patients may positively benefit from intraarticular delivery of a local analgesic to decrease overall pain levels and reduce the need for opioids following surgery. With no noted increase in infection risk, intraarticular delivery may also provide an effective alternative for pain relief in the immediate postoperative time period without the disadvantages encountered with epidural anesthesia, regional nerve blockade and patient controlled analgesia pumps.
"This study opens up a potential new option for better pain management post-surgery for our knee replacement patients. Though further study is needed, these initial results are promising," says Nitin Goyal, MD, of the Rothman Institute at Jefferson, an author on the study.
Additional authors on the study include: Nitin Goyal, MD; Javad Parvizi, MD; William Hozack, MD; Matthew Austin, MD; and James McKenzie, all with the Rothman Institute at Thomas Jefferson University Hospital.
About Thomas Jefferson University Hospitals
Thomas Jefferson University Hospitals (TJUH) are dedicated to excellence in patient care, patient safety and the quality of the healthcare experience. Consistently ranked by U.S. News & World Report among the nation's top hospitals, Thomas Jefferson University Hospital, established in 1825, has over 900 licensed acute care beds with major programs in a wide range of clinical specialties. TJUH is one of the few hospitals in the U.S. that is both a Level 1 Trauma Center and a federally-designated regional spinal cord injury center. TJUH patient care facilities include Jefferson Hospital for Neuroscience, the region's only dedicated hospital for neuroscience, Methodist Hospital in South Philadelphia, and additional patient care facilities throughout Pennsylvania and New Jersey. TJUH partners with its education affiliate, Thomas Jefferson University.
Lee-Ann Landis | EurekAlert!
Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena
Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
18.12.2017 | Information Technology
18.12.2017 | Physics and Astronomy
18.12.2017 | Agricultural and Forestry Science